ICON plc/$ICLR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ICON plc
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
- Ticker
- $ICLR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 40,200
- Headquarters
- Dublin, Ireland
- Website
- www.iconplc.com
ICON plc Metrics
BasicAdvanced
$14B
501.47
$0.35
1.20
-
Price and volume
Market cap
$14B
Beta
1.2
52-week high
$203.91
52-week low
$66.57
Average daily volume
987K
Financial strength
Current ratio
0.953
Quick ratio
0.924
Long term debt to equity
0.236
Total debt to equity
0.376
Interest coverage (TTM)
1.32%
Profitability
EBITDA (TTM)
523.481
Gross margin (TTM)
23.91%
Net profit margin (TTM)
0.33%
Operating margin (TTM)
3.09%
Effective tax rate (TTM)
68.65%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
0.97%
Return on equity (TTM)
0.29%
Valuation
Price to earnings (TTM)
501.475
Price to revenue (TTM)
1.622
Price to book
1.44
Price to tangible book (TTM)
-5.43
Price to free cash flow (TTM)
14.534
Free cash flow yield (TTM)
6.88%
Free cash flow per share (TTM)
12.05
Growth
Revenue change (TTM)
3.26%
Earnings per share change (TTM)
-96.23%
3-year revenue growth (CAGR)
1.62%
10-year revenue growth (CAGR)
17.82%
3-year earnings per share growth (CAGR)
-61.62%
10-year earnings per share growth (CAGR)
-22.25%
What the Analysts think about ICON plc
Analyst ratings (Buy, Hold, Sell) for ICON plc stock.
Analyst projections of the future price of ICON plc stock.
Bulls say / Bears say
Commercial momentum has improved sharply: Q2 net bookings reached $3.1 billion, giving a 1.51 times net book-to-bill, while backlog rose to $23.4 billion. This provides a substantial base of contracted work if ICON can convert it at healthier margins. (ICON plc)
The pipeline is becoming more supportive of future growth: RFP flow rose 22% sequentially and Phase III opportunities made up about half of total opportunity volume, versus roughly 40% a year earlier. ICON also reported improving biotech activity and said China revenue could rise by as much as 20% in 2026, adding growth channels beyond large pharma. (Stock Analysis, Yahoo Finance)
ICON is investing in AI through its Orbis platform and partnerships with Microsoft and Anthropic. Agents already in production have reportedly reduced SDTM-to-SAS coding cycle time by about 30%, which could lower administrative work, improve delivery and strengthen differentiation if rolled out widely. (RD World Online, ICON plc)
Profitability remains under pressure: Q2 adjusted EBITDA fell 21.7% year on year and the margin dropped to 15.9% from 20.5%, despite revenue rising 1.2%. The recovery case therefore depends on cost actions and better mix translating into earnings, not just sales growth. (ICON plc, Yahoo Finance)
The headline bookings strength is not all high-quality fee revenue: elevated pass-through activity boosted Q2 bookings, while direct-fee book-to-bill was lower at 1.2x. Large-pharma RFP flow moderated and biotech generated more preliminary proposals that historically convert at lower rates, which could make future growth less dependable. (Yahoo Finance, Stock Analysis)
ICON’s audit committee investigation identified issues with certain accounting practices, and management said it is strengthening the control environment. That leaves reporting and execution risk for investors to monitor while the company is also trying to restore profitability. (ICON plc)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
ICON plc Financial Performance
Revenues and expenses
ICON plc Earnings Performance
Company profitability
Upcoming events
No upcoming events
ICON plc News
AllArticlesVideos
Funds containing ICON plc
AllUSDEURGBP
Fund name | Fund size | $ICLR weighting |
|---|---|---|
Invesco Dow Jones Islamic Global Developed Markets$IGDA | $1.1B | 0.02% |
iShares USD Corporate Bond€LQDA | €2.9B | 0.02% |
iShares USD Corporate Bond£LQDS | £2.5B | 0.02% |
Amundi Prime All Country World€WEBN | €3.2B | 0.02% |
L&G Global Equity£LGGG | $2B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.